fda approves first oral glp-1 obesity drug august 21 2025 Orforglipron, approved as Foundayo on April 1, 2026, adds another option for chronic weight management in adults with or overweight plus at least one weight-related condition. The clinical relevance FDA approves first-ever oral GLP-1RA

Its ideal for athletes, professionals, and anyone looking for sustained energy and mental sharpness without the crash

Common side effects include temporary redness, swelling, and bruising at the injection site, which usually subsides within a few days

It is essential for protein synthesis and cell division, two processes required for healthy hair production

For instance, 5 g/mL of grape seed extract (GSE) inhibited d-galactose-induced apoptosis in vitro , but higher concentrations (50 and 100 g/mL) of GSE and GSPB2 for 24 h reduced the survival rates of hGC cells and KGN cell lines by approximately 20% and 50%, respectively (Roberts et al., 2014)